EMA Post Authorisation Guidance Faces Evidence Gaps After 10 Years
Decision brief
Answer first · skim in under a minute
EMA post authorisation guidance is central to how the EU tracks safety and lifecycle changes after approval. For BD teams, investors, and analysts, the key issue is what the framework can prove today—and where incomplete evidence still limits decision-making.
EMA Post authorisation guidance is how the EU manages medicines after centralised approval. For BD teams and investors, the practical question is what PASS, Type IA variations, and IRIS marketing-status reporting can prove today—and where the evidence base still leaves open risk.
Contents10 sections
Key Takeaways
- Post-authorisation work covers variations, pharmacovigilance (including PASS), and marketing-status reporting for centrally authorised products (CAPs).
- Type IA variations are low-impact changes implemented under predefined conditions; unfavourable outcomes push MAHs back to the correct procedural route.
- As of July 2021, EMA uses IRIS to collect CAP marketing-status notifications for EU/EEA Member States.
- Scientific advice remains available in the post-authorisation phase for study design, but it does not pre-judge benefit–risk at assessment.
What does EMA Post authorisation guidance cover?
After European Commission authorisation, marketing authorisation holders (MAHs) must keep the dossier and product information current and meet pharmacovigilance duties. The EMA’s post-authorisation procedural advice for the centralised procedure is the operational Q&A for those filings.
That document is guidance, not a substitute for EU legislation. MAHs still must meet Volume 2 / Notice to Applicants and applicable regulations. Pre-submission dialogue with EMA/(Co-)Rapporteurs is recommended for complex overlapping submissions.
Why do PASS still leave evidence gaps?
A post-authorisation safety study (PASS) is carried out after authorisation to obtain further information on a medicine’s safety, or to measure the effectiveness of risk-management measures. PASS can be imposed or voluntary, interventional or non-interventional.
For deal diligence, the gap is often timing and completeness: a PASS commitment signals residual uncertainty at approval, but public materials may not show whether the study met its protocol objectives on schedule. Teams should treat unfinished or delayed PASS as a portfolio-risk flag, not as proof of a safety failure.
Type IA variations and unfavourable outcomes
Type IA variations cover changes with minimal impact on quality, safety, or efficacy when implemented under predefined conditions. They are meant to streamline low-impact lifecycle maintenance.
If Type IA conditions are not met or the dossier is deficient, the MAH typically must revert the impacted change and resubmit via the appropriate route (for example Type IB or Type II). That resubmission path—and any temporary compliance exposure—is the BD-relevant detail, not the Type IA label alone.
IRIS marketing-status reporting since July 2021
Per EMA’s page on notifying a change of marketing status, as of July 2021 the Agency uses the IRIS database to collect marketing-status notifications for CAPs and to share an up-to-date overview with EU Member States and the European Commission.
- As of end of July 2021, EMA requests CAP MAHs to submit marketing-status notifications via IRIS.
- Baseline data for already marketed CAPs were uploaded during a multi-month transition; after baseline entry, changes continue in IRIS.
- Marketing-status data shared this way are for regulators; they are not a public commercial launch dashboard.
Can scientific advice close post-approval gaps?
EMA scientific advice and protocol assistance can be requested during initial development or later in the post-authorisation phase. Post-authorisation requests often cover new formulations, manufacturing changes, extensions of indication, or design of post-authorisation efficacy or safety studies.
Scientific advice looks at how to generate robust evidence. It does not pre-evaluate study results or conclude that benefits outweigh risks. Compliance with advice can improve dossier quality, but it is not a marketing-authorisation guarantee.
What remains unproven for investors
EMA guidance pages do not publish a single scorecard proving whether the post-authorisation system has become more or less stringent over a decade, or whether real-world evidence is systematically closing confirmatory gaps. Claims that require product-level PASS completion rates should be checked against the specific medicine’s assessment reports and imposed conditions—not inferred from procedural Q&As alone.
Related NovaPharma coverage
- EMA board backs Ebola response, flags 2025 annual report
- EMA Tightens Liver Safety Checks for Tavneos
- EMA approved 104 human medicines in 2025: what changed
Frequently Asked Questions
What is EMA Post authorisation guidance for?
It is the EMA’s procedural and pharmacovigilance framework for lifecycle changes after a centralised marketing authorisation, including variations, PASS, and marketing-status notifications.
What are post-authorisation safety studies (PASS)?
PASS are studies carried out after authorisation to obtain further information on a medicine’s safety or to measure the effectiveness of risk-management measures.
How do MAHs report CAP marketing status to EMA?
As of July 2021, EMA collects marketing-status notifications for centrally authorised products via the IRIS platform rather than email-only workflows.
